Journal Article
. 2018 Jun; 3(11):.
doi: 10.1172/jci.insight.120626.

Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors

Ee Lyn Lim 1 Fiorella M Cugliandolo 1 Dalya R Rosner 1 David Gyori 1 Rahul Roychoudhuri 1 Klaus Okkenhaug 1 
Affiliations
  • PMID: 29875319
  •     50 References
  •     15 citations

Abstract

Multiple modes of immunosuppression restrain immune function within tumors. We previously reported that phosphoinositide 3-kinase δ (PI3Kδ) inactivation in mice confers resistance to a range of tumor models by disrupting immunosuppression mediated by regulatory T cells (Tregs). The PI3Kδ inhibitor idelalisib has proven highly effective in the clinical treatment of chronic lymphocytic leukemia and the potential to extend the use of PI3Kδ inhibitors to nonhematological cancers is being evaluated. In this work, we demonstrate that the antitumor effect of PI3Kδ inactivation is primarily mediated through the disruption of Treg function, and correlates with tumor dependence on Treg immunosuppression. Compared with Treg-specific PI3Kδ deletion, systemic PI3Kδ inactivation is less effective at conferring resistance to tumors. We show that PI3Kδ deficiency impairs the maturation and reduces the capacity of CD8+ cytotoxic T lymphocytes (CTLs) to kill tumor cells in vitro, and to respond to tumor antigen-specific immunization in vivo. PI3Kδ inactivation antagonized the antitumor effects of tumor vaccines and checkpoint blockade therapies intended to boost the CD8+ T cell response. These findings provide insights into mechanisms by which PI3Kδ inhibition promotes antitumor immunity and demonstrate that the mechanism is distinct from that mediated by immune checkpoint blockade.

Keywords: Adaptive immunity; Cancer immunotherapy; Immunology; Oncology; Signal transduction.

Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells.
David K Finlay, Ella Rosenzweig, +6 authors, Doreen A Cantrell.
J Exp Med, 2012 Nov 28; 209(13). PMID: 23183047    Free PMC article.
Highly Cited.
Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.
Joseph G Crompton, Madhusudhanan Sukumar, +21 authors, Nicholas P Restifo.
Cancer Res, 2014 Nov 30; 75(2). PMID: 25432172    Free PMC article.
Highly Cited.
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858804    Free PMC article.
Highly Cited. Review.
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
Enfu Hui, Jeanne Cheung, +8 authors, Ronald D Vale.
Science, 2017 Mar 11; 355(6332). PMID: 28280247    Free PMC article.
Highly Cited.
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Ajay K Gopal, Brad S Kahl, +19 authors, Gilles A Salles.
N Engl J Med, 2014 Jan 24; 370(11). PMID: 24450858    Free PMC article.
Highly Cited.
Signaling by the phosphoinositide 3-kinase family in immune cells.
Klaus Okkenhaug.
Annu Rev Immunol, 2013 Jan 22; 31. PMID: 23330955    Free PMC article.
Highly Cited. Review.
PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes.
Eva Maria Putz, Michaela Prchal-Murphy, +8 authors, Eva Zebedin-Brandl.
PLoS One, 2012 Jul 19; 7(7). PMID: 22808277    Free PMC article.
Complete but curtailed T-cell response to very low-affinity antigen.
Dietmar Zehn, Sarah Y Lee, Michael J Bevan.
Nature, 2009 Feb 03; 458(7235). PMID: 19182777    Free PMC article.
Highly Cited.
Studies in antibody response of mice to tumour inoculation.
P A GORER.
Br J Cancer, 1950 Dec 01; 4(4). PMID: 14801344    Free PMC article.
Highly Cited.
PI3K in lymphocyte development, differentiation and activation.
Klaus Okkenhaug, Bart Vanhaesebroeck.
Nat Rev Immunol, 2003 Apr 02; 3(4). PMID: 12669022
Highly Cited. Review.
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.
Richard V Parry, Jens M Chemnitz, +6 authors, James L Riley.
Mol Cell Biol, 2005 Oct 18; 25(21). PMID: 16227604    Free PMC article.
Highly Cited.
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Blanca Homet Moreno, Jesse M Zaretsky, +11 authors, Antoni Ribas.
Cancer Immunol Res, 2016 Sep 04; 4(10). PMID: 27589875    Free PMC article.
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice.
Jeong M Kim, Jeffrey P Rasmussen, Alexander Y Rudensky.
Nat Immunol, 2006 Dec 01; 8(2). PMID: 17136045
Highly Cited.
PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells.
Jacob S Bowers, Kinga Majchrzak, +7 authors, Chrystal M Paulos.
Front Immunol, 2017 Oct 17; 8. PMID: 29033940    Free PMC article.
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
David Gyori, Ee Lyn Lim, +6 authors, Phillip T Hawkins.
JCI Insight, 2018 Jun 08; 3(11). PMID: 29875321    Free PMC article.
Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity.
W Joost Lesterhuis, Joanne Salmons, +6 authors, Richard A Lake.
PLoS One, 2013 Apr 30; 8(4). PMID: 23626745    Free PMC article.
Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3⁺ regulatory T cells.
Wim Pierson, Bénédicte Cauwe, +17 authors, Adrian Liston.
Nat Immunol, 2013 Jul 16; 14(9). PMID: 23852275    Free PMC article.
Highly Cited.
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors.
Susan Gilfillan, Christopher J Chan, +6 authors, Marco Colonna.
J Exp Med, 2008 Nov 26; 205(13). PMID: 19029380    Free PMC article.
The PI3K Pathway in Human Disease.
David A Fruman, Honyin Chiu, +3 authors, Robert T Abraham.
Cell, 2017 Aug 13; 170(4). PMID: 28802037    Free PMC article.
Highly Cited. Review.
Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition.
Rasha Abu Eid, Shamim Ahmad, +10 authors, Samir N Khleif.
Cancer Res, 2017 Jun 16; 77(15). PMID: 28615225
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure.
T H Corbett, D P Griswold, +2 authors, F M Schabel.
Cancer Res, 1975 Sep 11; 35(9). PMID: 1149045
Highly Cited.
Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy.
Alison Taylor, David Rothstein, Christopher E Rudd.
Cancer Res, 2017 Oct 22; 78(3). PMID: 29055015
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
I Brian Greenwell, Andrew Ip, Jonathon B Cohen.
Oncology (Williston Park), 2017 Nov 28; 31(11). PMID: 29179250
Review.
Introduction of soluble protein into the class I pathway of antigen processing and presentation.
M W Moore, F R Carbone, M J Bevan.
Cell, 1988 Sep 09; 54(6). PMID: 3261634
Highly Cited.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, +20 authors, KEYNOTE-006 investigators.
N Engl J Med, 2015 Apr 22; 372(26). PMID: 25891173
Highly Cited.
Generation of CD8 T cell memory is regulated by IL-12.
Erika L Pearce, Hao Shen.
J Immunol, 2007 Aug 07; 179(4). PMID: 17675465
Highly Cited.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S Weber, Sandra P D'Angelo, +25 authors, James Larkin.
Lancet Oncol, 2015 Mar 22; 16(4). PMID: 25795410
Highly Cited.
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
Ajay V Maker, Peter Attia, Steven A Rosenberg.
J Immunol, 2005 Nov 23; 175(11). PMID: 16301685    Free PMC article.
The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling.
Ozcan Met, Mingjun Wang, +3 authors, Mogens H Claesson.
Cancer Lett, 2006 Jan 10; 231(2). PMID: 16399226
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Klaus Okkenhaug, Mariona Graupera, Bart Vanhaesebroeck.
Cancer Discov, 2016 Sep 23; 6(10). PMID: 27655435    Free PMC article.
Highly Cited. Review.
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.
Khaled Ali, Dalya R Soond, +11 authors, Bart Vanhaesebroeck.
Nature, 2014 Jun 12; 510(7505). PMID: 24919154    Free PMC article.
Highly Cited.
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
Nikolaos Patsoukis, Lequn Li, +2 authors, Vassiliki A Boussiotis.
Mol Cell Biol, 2013 Jun 05; 33(16). PMID: 23732914    Free PMC article.
Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia.
Joanna Baginska, Elodie Viry, +11 authors, Bassam Janji.
Proc Natl Acad Sci U S A, 2013 Oct 09; 110(43). PMID: 24101526    Free PMC article.
Highly Cited.
T cell receptor antagonist peptides induce positive selection.
K A Hogquist, S C Jameson, +3 authors, F R Carbone.
Cell, 1994 Jan 14; 76(1). PMID: 8287475
Highly Cited.
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.
Matthew Kraman, Paul J Bambrough, +6 authors, Douglas T Fearon.
Science, 2010 Nov 06; 330(6005). PMID: 21051638
Highly Cited.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R Furman, Jeff P Sharman, +24 authors, Susan M O'Brien.
N Engl J Med, 2014 Jan 24; 370(11). PMID: 24450857    Free PMC article.
Highly Cited.
Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.
Toshihiro Nagato, Young-Ran Lee, Yasuaki Harabuchi, Esteban Celis.
Clin Cancer Res, 2014 Jan 07; 20(5). PMID: 24389326    Free PMC article.
PI3Kδ Regulates the Magnitude of CD8+ T Cell Responses after Challenge with Listeria monocytogenes.
Verity Q Pearce, Hicham Bouabe, +2 authors, Klaus Okkenhaug.
J Immunol, 2015 Aug 28; 195(7). PMID: 26311905    Free PMC article.
Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces.
Yuri P Rubtsov, Jeffrey P Rasmussen, +9 authors, Alexander Y Rudensky.
Immunity, 2008 Apr 05; 28(4). PMID: 18387831
Highly Cited.
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.
Benjamin L Lampson, Siddha N Kasar, +16 authors, Jennifer R Brown.
Blood, 2016 Jun 02; 128(2). PMID: 27247136    Free PMC article.
Highly Cited.
Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.
Klaus Okkenhaug, Antonio Bilancio, +9 authors, Bart Vanhaesebroeck.
Science, 2002 Jul 20; 297(5583). PMID: 12130661
Highly Cited.
Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis.
Cecilia Cs Yeung, David M Hockenbery, +6 authors, Francesc Bosch.
Future Oncol, 2018 Mar 24; 14(22). PMID: 29569483
Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy.
Shamim Ahmad, Rasha Abu-Eid, +8 authors, Samir N Khleif.
Cancer Res, 2017 Jan 22; 77(8). PMID: 28108509
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Haidong Dong, Scott E Strome, +10 authors, Lieping Chen.
Nat Med, 2002 Jul 02; 8(8). PMID: 12091876
Highly Cited.
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.
Alice O Kamphorst, Andreas Wieland, +17 authors, Rafi Ahmed.
Science, 2017 Mar 11; 355(6332). PMID: 28280249    Free PMC article.
Highly Cited.
Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.
Ergun Kocak, Kenneth Lute, +8 authors, Yang Liu.
Cancer Res, 2006 Jul 20; 66(14). PMID: 16849577
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves.
William G Kerr, John D Chisholm.
J Immunol, 2018 Dec 28; 202(1). PMID: 30587569    Free PMC article.
Review.
Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.
Ee Lyn Lim, Klaus Okkenhaug.
Immunology, 2019 May 21; 157(3). PMID: 31107985    Free PMC article.
Review.
Checkpoint inhibitor blockade and epigenetic reprogrammability in CD8+ T-cell activation and exhaustion.
José Belizário, Maria Fernanda Destro Rodrigues.
Ther Adv Vaccines Immunother, 2020 Mar 25; 8. PMID: 32206744    Free PMC article.
Review.
Control of T lymphocyte fate decisions by PI3K signaling.
Benjamin Murter, Lawrence P Kane.
F1000Res, 2020 Oct 08; 9. PMID: 33024547    Free PMC article.
Review.
Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3.
Sarah Nicol Lauder, Kathryn Smart, +15 authors, Awen Gallimore.
J Immunother Cancer, 2020 Oct 24; 8(2). PMID: 33093155    Free PMC article.
Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting?
Pierre Stéphan, Raphaëlle Lautraite, Allison Voisin, Yenkel Grinberg-Bleyer.
Cancers (Basel), 2020 Nov 05; 12(11). PMID: 33143070    Free PMC article.
Review.
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
Giuseppe Curigliano, Rashmi R Shah.
Drug Saf, 2019 Jan 17; 42(2). PMID: 30649751
Review.
A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer.
Giulia Marelli, Louisa S Chard Dunmall, +9 authors, Yaohe Wang.
J Immunother Cancer, 2021 Jan 28; 9(1). PMID: 33500259    Free PMC article.
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Ebru Aydin, Sebastian Faehling, +3 authors, Philipp M Roessner.
Front Immunol, 2021 Feb 09; 11. PMID: 33552053    Free PMC article.
Review.
PI3-Kinase p110α Deficiency Modulates T Cell Homeostasis and Function and Attenuates Experimental Allergic Encephalitis in Mature Mice.
José M Rojo, María Montes-Casado, +3 authors, Pilar Portolés.
Int J Mol Sci, 2021 Aug 28; 22(16). PMID: 34445401    Free PMC article.
Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Sho Isoyama, Shigeyuki Mori, +6 authors, Hiroyoshi Nishikawa.
J Immunother Cancer, 2021 Aug 28; 9(8). PMID: 34446575    Free PMC article.
A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma.
Brittany Fitzgerald, Kelli A Connolly, +7 authors, Nikhil S Joshi.
Cell Rep Methods, 2021 Oct 12; 1(5). PMID: 34632444    Free PMC article.
PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients.
Chiara Tarantelli, Lisa Argnani, Pier Luigi Zinzani, Francesco Bertoni.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771694    Free PMC article.
Review.
Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
Zhi Qi, Zihan Xu, +6 authors, Hong Wu.
Nat Commun, 2022 Jan 12; 13(1). PMID: 35013322    Free PMC article.
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Mengling Wu, Qianrui Huang, +4 authors, Yong Xia.
J Hematol Oncol, 2022 Mar 14; 15(1). PMID: 35279217    Free PMC article.
Review.